246 related articles for article (PubMed ID: 27416955)
1. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
[TBL] [Abstract][Full Text] [Related]
2. Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.
Zalles M; Smith N; Ziegler J; Saunders D; Remerowski S; Thomas L; Gulej R; Mamedova N; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Wiley G; Brown C; Battiste J; Wren JD; Towner RA
J Cell Mol Med; 2020 Jan; 24(2):1738-1749. PubMed ID: 31863639
[TBL] [Abstract][Full Text] [Related]
3. Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment.
Ziegler J; Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Patel M; Wren JD; Lupu F; Battiste J; Towner RA
Am J Nucl Med Mol Imaging; 2019; 9(1):93-109. PubMed ID: 30911439
[TBL] [Abstract][Full Text] [Related]
4. Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model.
Zalles M; Smith N; Saunders D; Saran T; Thomas L; Gulej R; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Battiste J; Towner RA
Transl Oncol; 2020 Mar; 13(3):100737. PubMed ID: 32208341
[TBL] [Abstract][Full Text] [Related]
5. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
[TBL] [Abstract][Full Text] [Related]
6. ELTD1 as a multi-focal target for malignant gliomas: preclinical studies.
Zalles M; Smith N; Saunders D; Guzman M; Lerner M; Fung KM; Babu A; Battiste J; Chung J; Hwang K; Jin J; Towner RA
Neurooncol Adv; 2021; 3(1):vdab132. PubMed ID: 34704036
[TBL] [Abstract][Full Text] [Related]
7. A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.
Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Battiste J; Towner RA
J Cell Mol Med; 2022 Jan; 26(2):570-582. PubMed ID: 34910361
[TBL] [Abstract][Full Text] [Related]
8. ELTD1, a potential new biomarker for gliomas.
Towner RA; Jensen RL; Colman H; Vaillant B; Smith N; Casteel R; Saunders D; Gillespie DL; Silasi-Mansat R; Lupu F; Giles CB; Wren JD
Neurosurgery; 2013 Jan; 72(1):77-90; discussion 91. PubMed ID: 23096411
[TBL] [Abstract][Full Text] [Related]
9. ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
Huang H; Georganaki M; Conze LL; Laviña B; van Hooren L; Vemuri K; van de Walle T; Ramachandran M; Zhang L; Pontén F; Bergqvist M; Smits A; Betsholtz C; Dejana E; Magnusson PU; He L; Lugano R; Dimberg A
Neuro Oncol; 2022 Mar; 24(3):398-411. PubMed ID: 34347079
[TBL] [Abstract][Full Text] [Related]
10. Multivoxel ¹H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting.
Hamans B; Navis AC; Wright A; Wesseling P; Heerschap A; Leenders W
Neuro Oncol; 2013 Dec; 15(12):1615-24. PubMed ID: 24158109
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
12. MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.
Seshadri M; Ciesielski MJ
J Cereb Blood Flow Metab; 2009 Aug; 29(8):1373-82. PubMed ID: 19458603
[TBL] [Abstract][Full Text] [Related]
13. Invasion as limitation to anti-angiogenic glioma therapy.
Lamszus K; Kunkel P; Westphal M
Acta Neurochir Suppl; 2003; 88():169-77. PubMed ID: 14531575
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma.
Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J
Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979
[TBL] [Abstract][Full Text] [Related]
15. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
16. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis.
Anderson JC; Grammer JR; Wang W; Nabors LB; Henkin J; Stewart JE; Gladson CL
Cancer Biol Ther; 2007 Mar; 6(3):454-62. PubMed ID: 17384534
[TBL] [Abstract][Full Text] [Related]
17. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Navis AC; Hamans BC; Claes A; Heerschap A; Jeuken JW; Wesseling P; Leenders WP
J Pathol; 2011 Apr; 223(5):626-34. PubMed ID: 21341272
[TBL] [Abstract][Full Text] [Related]
18. ELTD1 facilitates glioma proliferation, migration and invasion by activating JAK/STAT3/HIF-1α signaling axis.
Li J; Shen J; Wang Z; Xu H; Wang Q; Chai S; Fu P; Huang T; Anas O; Zhao H; Li J; Xiong N
Sci Rep; 2019 Sep; 9(1):13904. PubMed ID: 31554859
[TBL] [Abstract][Full Text] [Related]
19. ELTD1 as a biomarker for multiple sclerosis: Pre-clinical molecular-targeted studies in a mouse experimental autoimmune encephalomyelitis model.
Towner RA; Smith N; Zalles M; Morris S; Toliver M; Saunders D; Lerner M; Kumar G; Axtell RC
Mult Scler Relat Disord; 2021 Apr; 49():102786. PubMed ID: 33517175
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
